1
Clinical Trials associated with PURETHAL Grasses(HAL Allergy Holding BV)A Prospective, Randomized, Open, Multi-centre Study to Assess Safety of PURETHAL Grasses Given With a Rush Induction Schedule to Patients With Allergic Rhinoconjunctivitis
This study investigates the safety of two up-dosing regimen. The safety of PURETHAL Grasses will be evaluated in a rush regimen (maximum dose reached in 3 injections during 2 weeks) compared to the conventional regimen (maximum dose reached in 6 injections during 5 weeks).
The primary parameter will be the proportion of patients who experience systemic reactions > grade I within 24 hours after injection or who need more than 2 additional injections during the up-dosing phase until the maintenance dose has been reached.
It is expected that up-dosing PURETHAL Grasses according to the rush regimen is as safe as using the conventional regimen.
100 Clinical Results associated with PURETHAL Grasses(HAL Allergy Holding BV)
100 Translational Medicine associated with PURETHAL Grasses(HAL Allergy Holding BV)
100 Patents (Medical) associated with PURETHAL Grasses(HAL Allergy Holding BV)
100 Deals associated with PURETHAL Grasses(HAL Allergy Holding BV)